Cartilage damage in the knee joint/osteochondritis dissecans
Conditions
Interventions
IK-01 group
General name, etc.: Human (autologous) cartilage cell processed product (IK-01)
Dosage and administration, method of use: Transplantation to damaged area
MF group
General name, etc.: Micr
Sponsors
Hirosaki Lifescience Innovation, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Main study (1) Patients with localized traumatic cartilage damage in the knee joint (2) Patients with an IKDC score of less than 60 during screening (3) Patients with an ICRS or Outerbridge classification of III or IV (4) Patients with cartilage damage in the knee joint, with the area of cartilage damage judged to be 2 cm2 or more and 9 cm2 or less (5) Patients who have not received treatment for MF Sub-study,cohort 1 In addition to the main study criteria above, patients who meet the following criteria: (1) Patients who received MF treatment more than one year ago at the time of obtaining consent, but still have cartilage damage, or patients who were deemed ineffective in the main study Sub-study,cohort 2 (1) Patients with localized osteochondritis dissecans in the knee joint (2) Patients with an IKDC score of less than 60 at the screening stage (3) Patients with Nelson classification of III or IV on MRI images (4) Patients with osteochondritis dissecans with cartilage damage area judged to be 2 cm2 or more and 9 cm2 or less
Exclusion criteria
Exclusion criteria: (1) Patients with a history of treatment with human (autologous) cartilage-derived tissue regenerative medicine products or equivalent investigational products in the affected limb (2) Patients with cartilage damage or osteochondritis dissecans in both knee joints (3) Patients with knee osteoarthritis (4) Patients with two or more cartilage damage sites in one knee joint, or patients with localized cartilage damage requiring treatment in both knee joints (5) Patients with cartilage damage in the opposing joint surfaces
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) Change in IKDC score at 52 weeks after surgery (after IK-01 transplantation or MF) compared to preoperative values in patients with traumatic cartilage injury who did not undergo MF | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) For cohort 1 or 2, evaluate the proportion of subjects who achieved an increase of 20 or more in IKDC score at 52 weeks after surgery. | — |
Countries
none
Contacts
Public ContactRegenerative medicine Products Development
Hirosaki Lifescience Innovation, Inc.
Outcome results
None listed